Bioconjugate development continues to be a markedly complex proposition for drug developers, driven, in part, by increasingly intricate, disparate supply chains and a pervasive lack of expertise across the biotherapeutic sector. These challenges can serve to significantly harm a bioconjugate’s time-to-market, and finding a partner with the expertise needed to address the technical, regulatory, and market supply challenges inherent to bioconjugate development can be critical for biopharmaceutical companies.
Lonza Pharma & Biotech’s Iwan Bertholjotti, director of commercial development of bioconjugates, and Dr. Bernhard Stump, head of development of bioconjugates, recently hosted the webinar The Challenges of Moving a Bioconjugate Candidate from Clinic to Market. In it, the pair discussed the complexity and uncertainty that defines the bioconjugates market, as well as how companies should position themselves to mitigate that uncertainty at every stage of development. The following Q&A session was held after this webinar, where Bertholjotti and Stump addressed questions from attendees regarding Lonza’s expertise and history in the space.